Department of Radiation Oncology, Duke Cancer Institute, Durham, NC, USA.
Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Oral Oncol. 2023 Apr;139:106362. doi: 10.1016/j.oraloncology.2023.106362. Epub 2023 Mar 15.
To characterize factors including nodal burden, pre-treatment imaging, and other patient factors which may influence the role of ipsilateral neck radiotherapy (IRT) in tonsillar squamous cell carcinoma (SCC) with multiple involved ipsilateral nodes.
Patients with cT1-2N0-2bM0 (AJCC 7th edition) tonsillar SCC treated with definitive radiation therapy (RT) at Duke University Medical Center from 1/1/1990-10/1/2019 were identified. Patient, tumor, and treatment characteristics were compared between those that received bilateral neck RT (BRT) versus IRT. Recurrence-free survival (RFS) was estimated with Kaplan-Meier method. A subset analysis of patients with N2b disease was performed. Patterns of recurrence were analyzed.
120 patients with cT1-2N0-2b tonsillar SCC were identified, including 71 with N2b disease (BRT: n = 30; IRT: n = 41). Median follow-up was 80 months (range: 7-209). No N2b patients who received IRT had > 1 cm of soft palate/base of tongue extension. N2b patients treated with IRT had a median of 3 (range 2-9) involved lymph nodes, with median largest nodal dimension of 2.8 cm (range 1.3-4.8 cm). 93 % of N2b patients who received IRT had staging by PET/CT, and 100 % received IMRT. For N2b patients treated with IRT, there were no contralateral neck recurrences, and 10 year RFS was 95 % (95 % CI 82 %-98 %).
For patients treated with IRT for well-lateralized N2b tonsillar SCC, we observed high rates of local control with no observed contralateral neck recurrence. These data suggest that BRT is not universally necessary for patients with multiple involved ipsilateral nodes, particularly in the setting of baseline staging with PET/CT.
描述包括淋巴结受累程度、治疗前影像学检查以及其他患者因素在内的多种因素,这些因素可能影响多侧颈部淋巴结受累的扁桃体鳞状细胞癌(SCC)患者同侧颈部放疗(IRT)的作用。
在杜克大学医学中心,从 1990 年 1 月 1 日至 2019 年 10 月 1 日,对接受根治性放疗(RT)治疗的 cT1-2N0-2bM0(AJCC 第 7 版)扁桃体 SCC 患者进行了识别。比较接受双侧颈部放疗(BRT)与 IRT 的患者的患者、肿瘤和治疗特征。采用 Kaplan-Meier 法估计无复发生存率(RFS)。对 N2b 疾病患者进行了亚组分析。分析了复发模式。
共确定了 120 例 cT1-2N0-2b 扁桃体 SCC 患者,其中 71 例为 N2b 疾病患者(BRT:n=30;IRT:n=41)。中位随访时间为 80 个月(范围:7-209)。接受 IRT 的 N2b 患者无一例存在>1cm 的软腭/舌根延伸。接受 IRT 治疗的 N2b 患者的中位受累淋巴结数为 3 个(范围 2-9 个),最大淋巴结直径的中位数为 2.8cm(范围 1.3-4.8cm)。接受 IRT 的 93%的 N2b 患者进行了 PET/CT 分期,100%的患者接受了调强放疗(IMRT)。对于接受 IRT 的 N2b 患者,无对侧颈部复发,10 年 RFS 为 95%(95%CI 82%-98%)。
对于接受 IRT 治疗的多侧颈部淋巴结受累的扁桃体 SCC 患者,我们观察到局部控制率很高,且无对侧颈部复发。这些数据表明,对于基线有 PET/CT 分期的多侧淋巴结受累患者,BRT 并非普遍必要。